Why the study?
Does renal impairment cause false-positive or discrepant digoxin measurements on immunoassays due to an endogenous substance?
Does renal impairment cause false-positive or discrepant digoxin measurements on immunoassays due to an endogenous substance?
Patients with renal impairment possess an endogenous digoxin-like substance that can cause false-positive results and significant discrepancies across different digoxin immunoassays, compromising clinical interpretation.
Answers are grounded in this paper and cite their sources.
Clinicians should question digoxin immunoassay results in renal impairment; cross-sectional data leaves open endogenous interference and assay standardization.
Digoxin concentrations were measured in serum samples from 102 patients with renal impairment who were receiving digoxin therapy. Many patients had values that differed widely on several currently available immunoassays, with differences as great as 2.9 ng/mL. In contrast, patients with normal renal function who were receiving digoxin had few discrepant results, with the largest difference being 0.5 ng/mL. We also assayed serum samples from 54 patients with renal impairment not on digoxin therapy and found that more than 60% of these digoxin-free patients had false-positive digoxin values on most assays. Our data suggest that a substance with digoxin-like immunoactivity is present in many patients with renal insufficiency. This substance may seriously compromise the accuracy and interpretation of digoxin concentration measurements.
No takes yet. Share an insight, caveat, or question.
Steven W. Graves (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: